Reference 12e
The use of human papillomavirus testing (HPV) to monitor effectiveness of treatment of high-grade intra-epithelial abnormalities of the cervix
The use of human papillomavirus testing (HPV) to monitor effectiveness of treatment of high-grade intra-epithelial abnormalities of the cervix
Reference No. | 12e |
| Reference Name | The use of human papillomavirus testing (HPV) to monitor effectiveness of treatment of high-grade intra-epithelial abnormalities of the cervix |
| Advisory Panels | Professor Brendon Kearney (Chair and MSAC member) Professor Sydney Bell (MSAC member) Dr Paul Craft (MSAC member) Dr Ray Kirk (MSAC member) Dr Alistair Lochhead (Royal College of Pathologists of Australasia nominee) Dr Heather Mitchell (co-opted member) Dr Marion Saville (Australian Society of Cytology nominee) Dr Judy Straton (Department of Health and Ageing) Dr Lynnette Wray (Royal Australian College of Cytology nominee) Dr Christopher Hunter (Royal Australian and New Zealand College of Obstetrics and Gynaecology nominee) Ms Kathleen Mazzella (Consumers' Health Forum of Australia nominee) |
| Date Received by MSAC Secretariat | June 2001 |
| Stage 1 - Eligibility | Eligible |
| Stage 2 - Assessment | Completed |
| Stage 3 - Formulation of Advice to the Minister | This assessment was considered by the MSAC at the 17 March 2004 meeting. The MSAC recommended that on the strength of evidence pertaining to the use of high-risk HPV testing (HC-II or PCR) at 12 and 24 months following treatment of high-grade squamous intra-epithelial lesions of the cervix to monitor the effectiveness of treatment, public funding should be supported for this procedure. |
| Stage 4 - Decision | Endorsed by the Minister for Health and Ageing 22 June 2004 |
| Stage 5 - Implementation |  |
Page currency, Latest update: 30 March, 2009
